Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration.
Ohtake
Y
Y
Department of Emergency and Critical Care Medicine, Chiba University School of Medicine, Japan.
Hirasawa
H
H
Sugai
T
T
Oda
S
S
Shiga
H
H
Matsuda
K
K
Kitamura
N
N
D000925:Anticoagulants / Q000627:therapeutic use*; D001550:Benzamidines; D006146:Guanidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006440:Hemofiltration; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006493:Heparin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D006435:Renal Dialysis
D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; D006495:Heparin, Low-Molecular-Weight; D006493:Heparin; C032855:nafamostat